Inozyme Pharma Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2021
Period Ending	Aug '25 Aug 7, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2017 - 2021
Market Capitalization	284,619	255,929	164,797	112,155	110,694	-	Upgrade
Market Cap Growth	61.59%	55.30%	46.94%	1.32%	-	-	Upgrade
Enterprise Value	311,979	275,658	176,030	117,314	107,850	-	Upgrade
Last Close Price	711.30	639.30	411.62	281.24	275.99	-	Upgrade
PE Ratio	75.60	66.56	53.16	33.35	33.27	-	Upgrade
PS Ratio	8.84	8.43	6.60	5.10	6.71	-	Upgrade
PB Ratio	11.77	10.58	7.87	5.79	7.85	-	Upgrade
P/TBV Ratio	16.44	14.78	11.32	8.74	8.71	-	Upgrade
P/FCF Ratio	-	-	-	-	72.02	-	Upgrade
P/OCF Ratio	-	43.99	31.62	25.96	34.16	-	Upgrade
EV/Sales Ratio	9.69	9.08	7.05	5.34	6.53	-	Upgrade
EV/EBITDA Ratio	39.30	36.54	28.40	20.13	21.07	-	Upgrade
EV/EBIT Ratio	51.61	45.46	35.84	24.67	24.12	-	Upgrade
EV/FCF Ratio	-	-	-	-	70.17	-	Upgrade
Debt / Equity Ratio	1.06	1.06	0.65	0.35	0.18	0.36	Upgrade
Debt / EBITDA Ratio	3.22	3.29	2.15	1.13	0.50	0.85	Upgrade
Debt / FCF Ratio	-	-	-	-	1.67	1.21	Upgrade
Asset Turnover	-	0.63	0.74	0.91	0.99	1.01	Upgrade
Inventory Turnover	-	21.39	22.02	22.18	22.07	20.33	Upgrade
Quick Ratio	-	0.64	1.00	1.36	1.57	1.47	Upgrade
Current Ratio	-	0.83	1.21	1.61	1.83	1.62	Upgrade
Return on Equity (ROE)	-	18.39%	16.67%	21.85%	30.07%	27.63%	Upgrade
Return on Assets (ROA)	-	7.91%	9.04%	12.26%	16.72%	14.40%	Upgrade
Return on Capital (ROIC)	8.97%	9.00%	10.12%	13.88%	19.55%	17.44%	Upgrade
Return on Capital Employed (ROCE)	-	12.40%	14.40%	18.00%	26.40%	26.20%	Upgrade
Earnings Yield	1.32%	1.50%	1.88%	3.00%	3.00%	-	Upgrade
FCF Yield	-	-1.67%	-0.77%	-1.27%	1.39%	-	Upgrade
Buyback Yield / Dilution	0.01%	-	-	-0.74%	-4.32%	-1.42%	Upgrade

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.